PROPHYLAXIS WITH UROKINASE IN PEDIATRIC ONCOLOGY PATIENTS WITH CENTRAL VENOUS CATHETERS
This study evaluated the effects of urokinase in the prevention of central venous catheter (CVC)-related complications in children with malignancy. Fifteen patients with 16 CVCs (study group A) received an intraluminal application of urokinase (10,000 IU in each catheter lumen for 4 h) once a week....
Gespeichert in:
| Veröffentlicht in: | Pediatric hematology and oncology 2002, Vol.19 (3), p.173-179 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 179 |
|---|---|
| container_issue | 3 |
| container_start_page | 173 |
| container_title | Pediatric hematology and oncology |
| container_volume | 19 |
| creator | Kalmanti, Maria Germanakis, John Stiakaki, Eftichia Sfyridaki, Cathrin Christidou, Athanasia Tsetis, Dimitris Vardas, Panagiotis Charisis, George |
| description | This study evaluated the effects of urokinase in the prevention of central venous catheter (CVC)-related complications in children with malignancy. Fifteen patients with 16 CVCs (study group A) received an intraluminal application of urokinase (10,000 IU in each catheter lumen for 4 h) once a week. They were monitored prospectively with quantitative blood cultures and ultrasonography (color Doppler ultrasound of the great veins and echocardiography). The rate of complications was compared with that of 15 children with 19 CVCs without thromboprophylaxis, treated the previous year (control group B). The authors found a significantly lower incidence of CVC dysfunction (3/16 versus 13/19), no major thrombosis, fewer CVC-related bacteremias (2/16 versus 8/19), and a higher salvage of CVCs (1/16 versus 5/19 CVC removals due to persistent bacteremia) in the thromboprophylaxis group. Asymptomatic thrombosis rate was also lower (7/16 cases in group A versus 9/11 in group B when sonography was performed). No hemorrhagic complications were noted. Thromboprophylaxis with urokinase seems a safe and effective measure for reducing the rate of CVC-related complications. |
| doi_str_mv | 10.1080/088800102753541323 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_infor</sourceid><recordid>TN_cdi_informahealthcare_journals_10_1080_088800102753541323</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>11936730</sourcerecordid><originalsourceid>FETCH-LOGICAL-c436t-234b89dfaca24a952f3a62f71156cd3545fe0ca7df3d9a1c4dd0b04dfb75889e3</originalsourceid><addsrcrecordid>eNp9kE1Pg0AURSdGY2v1D7gwbFyi88HHkOiCIAqRAAFq7YpMZ5i0DS3N0Mb030tTjDEmXb23OOfmvQvALYIPCFL4CCmlECKIbZOYBiKYnIEhMjHSoWU552B4APSOoANw1bZLCCEmNr4EA4QcYtkEDsEkzZI0mEbuZ5hrk7AItHGWvIexm_taGGup_xK6RRZ6WhJ7SZS8TbXULUI_Lnra69bMjbQPP07Guea5ReAXfpZfgwvJ6ra66ecIjF_9wgv0LiP03EjnBrG2OibGjDpCMs6wwRwTS8IsLG2ETIuL7itTVpAzW0giHIa4IQScQUPImW1S6lRkBPAxl6umbVUly41arJjalwiWh5bK_y110t1R2uxmq0r8Kn0tHXDfA6zlrJaKrfmi_eWIZRJs2B33fOQWa9moFftqVC3KLdvXjfqRyMlDnv7484rV2zlnqiqXzU6tu-ZO_fENRYqNlA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>PROPHYLAXIS WITH UROKINASE IN PEDIATRIC ONCOLOGY PATIENTS WITH CENTRAL VENOUS CATHETERS</title><source>MEDLINE</source><source>Taylor & Francis Medical Library - CRKN</source><source>Access via Taylor & Francis</source><creator>Kalmanti, Maria ; Germanakis, John ; Stiakaki, Eftichia ; Sfyridaki, Cathrin ; Christidou, Athanasia ; Tsetis, Dimitris ; Vardas, Panagiotis ; Charisis, George</creator><creatorcontrib>Kalmanti, Maria ; Germanakis, John ; Stiakaki, Eftichia ; Sfyridaki, Cathrin ; Christidou, Athanasia ; Tsetis, Dimitris ; Vardas, Panagiotis ; Charisis, George</creatorcontrib><description>This study evaluated the effects of urokinase in the prevention of central venous catheter (CVC)-related complications in children with malignancy. Fifteen patients with 16 CVCs (study group A) received an intraluminal application of urokinase (10,000 IU in each catheter lumen for 4 h) once a week. They were monitored prospectively with quantitative blood cultures and ultrasonography (color Doppler ultrasound of the great veins and echocardiography). The rate of complications was compared with that of 15 children with 19 CVCs without thromboprophylaxis, treated the previous year (control group B). The authors found a significantly lower incidence of CVC dysfunction (3/16 versus 13/19), no major thrombosis, fewer CVC-related bacteremias (2/16 versus 8/19), and a higher salvage of CVCs (1/16 versus 5/19 CVC removals due to persistent bacteremia) in the thromboprophylaxis group. Asymptomatic thrombosis rate was also lower (7/16 cases in group A versus 9/11 in group B when sonography was performed). No hemorrhagic complications were noted. Thromboprophylaxis with urokinase seems a safe and effective measure for reducing the rate of CVC-related complications.</description><identifier>ISSN: 0888-0018</identifier><identifier>EISSN: 1521-0669</identifier><identifier>DOI: 10.1080/088800102753541323</identifier><identifier>PMID: 11936730</identifier><identifier>CODEN: PHONEN</identifier><language>eng</language><publisher>Philadelphia, PA: Informa UK Ltd</publisher><subject>Bacteremia - drug therapy ; Bacteremia - etiology ; Bacteremia - prevention & control ; Biological and medical sciences ; Blood. Blood coagulation. Reticuloendothelial system ; Catheterization, Central Venous - adverse effects ; Central Venous Catheter ; Child ; Child, Preschool ; Childhood Malignancy ; Humans ; Infant ; Male ; Medical sciences ; Neoplasms - complications ; Neoplasms - drug therapy ; Neoplasms - therapy ; Pharmacology. Drug treatments ; Plasminogen Activators - administration & dosage ; Plasminogen Activators - therapeutic use ; Prospective Studies ; Thrombosis - drug therapy ; Thrombosis - etiology ; Thrombosis - prevention & control ; Urokinase ; Urokinase-Type Plasminogen Activator - administration & dosage ; Urokinase-Type Plasminogen Activator - therapeutic use ; Urokinase-Type Plasminogen Activator - toxicity</subject><ispartof>Pediatric hematology and oncology, 2002, Vol.19 (3), p.173-179</ispartof><rights>2002 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted 2002</rights><rights>2002 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c436t-234b89dfaca24a952f3a62f71156cd3545fe0ca7df3d9a1c4dd0b04dfb75889e3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.tandfonline.com/doi/pdf/10.1080/088800102753541323$$EPDF$$P50$$Ginformaworld$$H</linktopdf><linktohtml>$$Uhttps://www.tandfonline.com/doi/full/10.1080/088800102753541323$$EHTML$$P50$$Ginformaworld$$H</linktohtml><link.rule.ids>314,780,784,4024,27923,27924,27925,59647,59753,60436,60542,61221,61256,61402,61437</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=13653247$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11936730$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kalmanti, Maria</creatorcontrib><creatorcontrib>Germanakis, John</creatorcontrib><creatorcontrib>Stiakaki, Eftichia</creatorcontrib><creatorcontrib>Sfyridaki, Cathrin</creatorcontrib><creatorcontrib>Christidou, Athanasia</creatorcontrib><creatorcontrib>Tsetis, Dimitris</creatorcontrib><creatorcontrib>Vardas, Panagiotis</creatorcontrib><creatorcontrib>Charisis, George</creatorcontrib><title>PROPHYLAXIS WITH UROKINASE IN PEDIATRIC ONCOLOGY PATIENTS WITH CENTRAL VENOUS CATHETERS</title><title>Pediatric hematology and oncology</title><addtitle>Pediatr Hematol Oncol</addtitle><description>This study evaluated the effects of urokinase in the prevention of central venous catheter (CVC)-related complications in children with malignancy. Fifteen patients with 16 CVCs (study group A) received an intraluminal application of urokinase (10,000 IU in each catheter lumen for 4 h) once a week. They were monitored prospectively with quantitative blood cultures and ultrasonography (color Doppler ultrasound of the great veins and echocardiography). The rate of complications was compared with that of 15 children with 19 CVCs without thromboprophylaxis, treated the previous year (control group B). The authors found a significantly lower incidence of CVC dysfunction (3/16 versus 13/19), no major thrombosis, fewer CVC-related bacteremias (2/16 versus 8/19), and a higher salvage of CVCs (1/16 versus 5/19 CVC removals due to persistent bacteremia) in the thromboprophylaxis group. Asymptomatic thrombosis rate was also lower (7/16 cases in group A versus 9/11 in group B when sonography was performed). No hemorrhagic complications were noted. Thromboprophylaxis with urokinase seems a safe and effective measure for reducing the rate of CVC-related complications.</description><subject>Bacteremia - drug therapy</subject><subject>Bacteremia - etiology</subject><subject>Bacteremia - prevention & control</subject><subject>Biological and medical sciences</subject><subject>Blood. Blood coagulation. Reticuloendothelial system</subject><subject>Catheterization, Central Venous - adverse effects</subject><subject>Central Venous Catheter</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Childhood Malignancy</subject><subject>Humans</subject><subject>Infant</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Neoplasms - complications</subject><subject>Neoplasms - drug therapy</subject><subject>Neoplasms - therapy</subject><subject>Pharmacology. Drug treatments</subject><subject>Plasminogen Activators - administration & dosage</subject><subject>Plasminogen Activators - therapeutic use</subject><subject>Prospective Studies</subject><subject>Thrombosis - drug therapy</subject><subject>Thrombosis - etiology</subject><subject>Thrombosis - prevention & control</subject><subject>Urokinase</subject><subject>Urokinase-Type Plasminogen Activator - administration & dosage</subject><subject>Urokinase-Type Plasminogen Activator - therapeutic use</subject><subject>Urokinase-Type Plasminogen Activator - toxicity</subject><issn>0888-0018</issn><issn>1521-0669</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1Pg0AURSdGY2v1D7gwbFyi88HHkOiCIAqRAAFq7YpMZ5i0DS3N0Mb030tTjDEmXb23OOfmvQvALYIPCFL4CCmlECKIbZOYBiKYnIEhMjHSoWU552B4APSOoANw1bZLCCEmNr4EA4QcYtkEDsEkzZI0mEbuZ5hrk7AItHGWvIexm_taGGup_xK6RRZ6WhJ7SZS8TbXULUI_Lnra69bMjbQPP07Guea5ReAXfpZfgwvJ6ra66ecIjF_9wgv0LiP03EjnBrG2OibGjDpCMs6wwRwTS8IsLG2ETIuL7itTVpAzW0giHIa4IQScQUPImW1S6lRkBPAxl6umbVUly41arJjalwiWh5bK_y110t1R2uxmq0r8Kn0tHXDfA6zlrJaKrfmi_eWIZRJs2B33fOQWa9moFftqVC3KLdvXjfqRyMlDnv7484rV2zlnqiqXzU6tu-ZO_fENRYqNlA</recordid><startdate>2002</startdate><enddate>2002</enddate><creator>Kalmanti, Maria</creator><creator>Germanakis, John</creator><creator>Stiakaki, Eftichia</creator><creator>Sfyridaki, Cathrin</creator><creator>Christidou, Athanasia</creator><creator>Tsetis, Dimitris</creator><creator>Vardas, Panagiotis</creator><creator>Charisis, George</creator><general>Informa UK Ltd</general><general>Taylor & Francis</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>2002</creationdate><title>PROPHYLAXIS WITH UROKINASE IN PEDIATRIC ONCOLOGY PATIENTS WITH CENTRAL VENOUS CATHETERS</title><author>Kalmanti, Maria ; Germanakis, John ; Stiakaki, Eftichia ; Sfyridaki, Cathrin ; Christidou, Athanasia ; Tsetis, Dimitris ; Vardas, Panagiotis ; Charisis, George</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c436t-234b89dfaca24a952f3a62f71156cd3545fe0ca7df3d9a1c4dd0b04dfb75889e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Bacteremia - drug therapy</topic><topic>Bacteremia - etiology</topic><topic>Bacteremia - prevention & control</topic><topic>Biological and medical sciences</topic><topic>Blood. Blood coagulation. Reticuloendothelial system</topic><topic>Catheterization, Central Venous - adverse effects</topic><topic>Central Venous Catheter</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Childhood Malignancy</topic><topic>Humans</topic><topic>Infant</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Neoplasms - complications</topic><topic>Neoplasms - drug therapy</topic><topic>Neoplasms - therapy</topic><topic>Pharmacology. Drug treatments</topic><topic>Plasminogen Activators - administration & dosage</topic><topic>Plasminogen Activators - therapeutic use</topic><topic>Prospective Studies</topic><topic>Thrombosis - drug therapy</topic><topic>Thrombosis - etiology</topic><topic>Thrombosis - prevention & control</topic><topic>Urokinase</topic><topic>Urokinase-Type Plasminogen Activator - administration & dosage</topic><topic>Urokinase-Type Plasminogen Activator - therapeutic use</topic><topic>Urokinase-Type Plasminogen Activator - toxicity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kalmanti, Maria</creatorcontrib><creatorcontrib>Germanakis, John</creatorcontrib><creatorcontrib>Stiakaki, Eftichia</creatorcontrib><creatorcontrib>Sfyridaki, Cathrin</creatorcontrib><creatorcontrib>Christidou, Athanasia</creatorcontrib><creatorcontrib>Tsetis, Dimitris</creatorcontrib><creatorcontrib>Vardas, Panagiotis</creatorcontrib><creatorcontrib>Charisis, George</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Pediatric hematology and oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kalmanti, Maria</au><au>Germanakis, John</au><au>Stiakaki, Eftichia</au><au>Sfyridaki, Cathrin</au><au>Christidou, Athanasia</au><au>Tsetis, Dimitris</au><au>Vardas, Panagiotis</au><au>Charisis, George</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>PROPHYLAXIS WITH UROKINASE IN PEDIATRIC ONCOLOGY PATIENTS WITH CENTRAL VENOUS CATHETERS</atitle><jtitle>Pediatric hematology and oncology</jtitle><addtitle>Pediatr Hematol Oncol</addtitle><date>2002</date><risdate>2002</risdate><volume>19</volume><issue>3</issue><spage>173</spage><epage>179</epage><pages>173-179</pages><issn>0888-0018</issn><eissn>1521-0669</eissn><coden>PHONEN</coden><abstract>This study evaluated the effects of urokinase in the prevention of central venous catheter (CVC)-related complications in children with malignancy. Fifteen patients with 16 CVCs (study group A) received an intraluminal application of urokinase (10,000 IU in each catheter lumen for 4 h) once a week. They were monitored prospectively with quantitative blood cultures and ultrasonography (color Doppler ultrasound of the great veins and echocardiography). The rate of complications was compared with that of 15 children with 19 CVCs without thromboprophylaxis, treated the previous year (control group B). The authors found a significantly lower incidence of CVC dysfunction (3/16 versus 13/19), no major thrombosis, fewer CVC-related bacteremias (2/16 versus 8/19), and a higher salvage of CVCs (1/16 versus 5/19 CVC removals due to persistent bacteremia) in the thromboprophylaxis group. Asymptomatic thrombosis rate was also lower (7/16 cases in group A versus 9/11 in group B when sonography was performed). No hemorrhagic complications were noted. Thromboprophylaxis with urokinase seems a safe and effective measure for reducing the rate of CVC-related complications.</abstract><cop>Philadelphia, PA</cop><pub>Informa UK Ltd</pub><pmid>11936730</pmid><doi>10.1080/088800102753541323</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0888-0018 |
| ispartof | Pediatric hematology and oncology, 2002, Vol.19 (3), p.173-179 |
| issn | 0888-0018 1521-0669 |
| language | eng |
| recordid | cdi_informahealthcare_journals_10_1080_088800102753541323 |
| source | MEDLINE; Taylor & Francis Medical Library - CRKN; Access via Taylor & Francis |
| subjects | Bacteremia - drug therapy Bacteremia - etiology Bacteremia - prevention & control Biological and medical sciences Blood. Blood coagulation. Reticuloendothelial system Catheterization, Central Venous - adverse effects Central Venous Catheter Child Child, Preschool Childhood Malignancy Humans Infant Male Medical sciences Neoplasms - complications Neoplasms - drug therapy Neoplasms - therapy Pharmacology. Drug treatments Plasminogen Activators - administration & dosage Plasminogen Activators - therapeutic use Prospective Studies Thrombosis - drug therapy Thrombosis - etiology Thrombosis - prevention & control Urokinase Urokinase-Type Plasminogen Activator - administration & dosage Urokinase-Type Plasminogen Activator - therapeutic use Urokinase-Type Plasminogen Activator - toxicity |
| title | PROPHYLAXIS WITH UROKINASE IN PEDIATRIC ONCOLOGY PATIENTS WITH CENTRAL VENOUS CATHETERS |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T07%3A33%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_infor&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=PROPHYLAXIS%20WITH%20UROKINASE%20IN%20PEDIATRIC%20ONCOLOGY%20PATIENTS%20WITH%20CENTRAL%20VENOUS%20CATHETERS&rft.jtitle=Pediatric%20hematology%20and%20oncology&rft.au=Kalmanti,%20Maria&rft.date=2002&rft.volume=19&rft.issue=3&rft.spage=173&rft.epage=179&rft.pages=173-179&rft.issn=0888-0018&rft.eissn=1521-0669&rft.coden=PHONEN&rft_id=info:doi/10.1080/088800102753541323&rft_dat=%3Cpubmed_infor%3E11936730%3C/pubmed_infor%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/11936730&rfr_iscdi=true |